ELVN vs LGND โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LGND Captures Institutional Edge (3โ1 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ligand Pharmaceuticals Inc. (LGND) driven by superior Valuation, Growth & Margin, Momentum & Technical while ELVN counters with relative strength in Options & Structure. Fundamentally, ELVN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus LGND at 25.8x Forward P/E and 14.4% operating margin (-31.8% YoY). In options structure, ELVN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against LGND sits in CONSOLIDATION (8th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ELVN | LGND | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.6B | $6.3B | Larger Scale | LGND |
| Trailing P/E Ratio Valuation | N/M | 127.0x | Lower Multiple | LGND |
| Forward P/E Ratio Valuation | N/M | 25.8x | Lower Multiple | LGND |
| Revenue Growth (YoY) Growth | +0.0% | -31.8% | Higher Growth | ELVN |
| Operating Margin (TTM) Profitability | 0.0% | 14.4% | Higher Margin | LGND |
| Net Profit Margin Profitability | 0.0% | 20.3% | Higher Margin | LGND |
| Return on Equity (ROE) Capital Efficiency | -16.8% | 5.4% | Higher ROE | LGND |
| 52-Week Range Position Momentum | 69% ($15โ$62) | 86% ($176โ$327) | Stronger Trend | LGND |
| Beta / 30D Volatility Risk Regime | 0.96ฮฒ ยท 60% Vol | 0.99ฮฒ ยท 38% Vol | Lower Realized Risk | LGND |
| Unified Institutional Score Composite Signal | 35.9 / 100 (SELL) | 42.9 / 100 (HOLD) | Higher Composite | LGND |